These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

802 related items for PubMed ID: 27246198

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
    Duintjer Tebbens RJ, Hampton LM, Thompson KM.
    BMC Infect Dis; 2016 May 26; 16():231. PubMed ID: 27230071
    [Abstract] [Full Text] [Related]

  • 3. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
    Thompson KM, Duintjer Tebbens RJ.
    BMC Infect Dis; 2015 Sep 17; 15():376. PubMed ID: 26382234
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
    Voorman A, Lyons H, Bennette C, Kovacs S, Makam JK, F Vertefeuille J, Tallis G.
    Vaccine; 2023 Apr 06; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
    [Abstract] [Full Text] [Related]

  • 6. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
    Hampton LM, Farrell M, Ramirez-Gonzalez A, Menning L, Shendale S, Lewis I, Rubin J, Garon J, Harris J, Hyde T, Wassilak S, Patel M, Nandy R, Chang-Blanc D, Immunization Systems Management Group of the Global Polio Eradication Initiative.
    MMWR Morb Mortal Wkly Rep; 2016 Sep 09; 65(35):934-8. PubMed ID: 27606675
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
    Duintjer Tebbens RJ, Hampton LM, Thompson KM.
    BMC Infect Dis; 2018 Apr 10; 18(1):165. PubMed ID: 29631539
    [Abstract] [Full Text] [Related]

  • 10. Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.
    Thompson KM, Duintjer Tebbens RJ.
    J Infect Dis; 2017 Jul 01; 216(suppl_1):S168-S175. PubMed ID: 28838198
    [Abstract] [Full Text] [Related]

  • 11. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
    Ramirez Gonzalez A, Farrell M, Menning L, Garon J, Everts H, Hampton LM, Dolan SB, Shendale S, Wanyoike S, Veira CL, Châtellier GMD, Kurji F, Rubin J, Boualam L, Chang Blanc D, Patel M.
    J Infect Dis; 2017 Jul 01; 216(suppl_1):S183-S192. PubMed ID: 28838179
    [Abstract] [Full Text] [Related]

  • 12. Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.
    Duintjer Tebbens RJ, Thompson KM.
    BMC Infect Dis; 2015 Sep 24; 15():390. PubMed ID: 26404780
    [Abstract] [Full Text] [Related]

  • 13. Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes.
    Thompson KM, Duintjer Tebbens RJ.
    BMC Infect Dis; 2015 Sep 17; 15():374. PubMed ID: 26381878
    [Abstract] [Full Text] [Related]

  • 14. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
    Alleman MM, Jorba J, Greene SA, Diop OM, Iber J, Tallis G, Goel A, Wiesen E, Wassilak SGF, Burns CC.
    MMWR Morb Mortal Wkly Rep; 2020 Apr 24; 69(16):489-495. PubMed ID: 32324719
    [Abstract] [Full Text] [Related]

  • 15. Strategic Response to an Outbreak of Circulating Vaccine-Derived Poliovirus Type 2 - Syria, 2017-2018.
    Mbaeyi C, Wadood ZM, Moran T, MJourn, Ather F, Stehling-Ariza T, Nikulin J, Al Safadi M, Iber J, Zomahoun L, Abourshaid N, Pang H, Collins N, Asghar H, Butt OUI, Burns CC, Ehrhardt D, Sharaf M.
    MMWR Morb Mortal Wkly Rep; 2018 Jun 22; 67(24):690-694. PubMed ID: 29927908
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of vaccine derived poliovirus type 2 outbreak response options: A randomized controlled trial, Karachi, Pakistan.
    Saleem AF, Yousafzai MT, Mach O, Khan A, Quadri F, Weldon WC, Oberste MS, Zaidi SS, Alam MM, Sutter RW, Zaidi AKM.
    Vaccine; 2018 Mar 20; 36(13):1766-1771. PubMed ID: 29477307
    [Abstract] [Full Text] [Related]

  • 17. Risk factors for the spread of vaccine-derived type 2 polioviruses after global withdrawal of trivalent oral poliovirus vaccine and the effects of outbreak responses with monovalent vaccine: a retrospective analysis of surveillance data for 51 countries in Africa.
    Cooper LV, Bandyopadhyay AS, Gumede N, Mach O, Mkanda P, Ndoutabé M, Okiror SO, Ramirez-Gonzalez A, Touray K, Wanyoike S, Grassly NC, Blake IM.
    Lancet Infect Dis; 2022 Feb 20; 22(2):284-294. PubMed ID: 34648733
    [Abstract] [Full Text] [Related]

  • 18. [Advances in researches of serotype 2 novel oral polio vaccine].
    Chen SY, Li Y, Yang JS, Yin XX.
    Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar 06; 55(3):413-417. PubMed ID: 33730837
    [Abstract] [Full Text] [Related]

  • 19. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
    Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM.
    Risk Anal; 2021 Feb 06; 41(2):320-328. PubMed ID: 32632925
    [Abstract] [Full Text] [Related]

  • 20. Monovalent type 2 OPV (mOPV2) management in the field: Interventions and lessons learned.
    Afsar A, Mallya A, Mohammed AAG, Anand S, Diomande VKF, Maufras du Châtellier G, Ather F.
    Vaccine; 2023 Apr 06; 41 Suppl 1():A79-A84. PubMed ID: 36642630
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.